RxDoctor Payments Data

Shelini Sooklal, MD

Gastroenterology · Wailuku, HINPI 1346516374

Payments from drug & device makers

What this record shows

This record is dominated by grants: $20,000 of the $20,783 with a category attached, or 96.2%. Boston Scientific accounts for 96.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $10,214 and has fallen 95.5% since, to $461 in 2025. Among gastroenterology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,783in general payments, 2019–2025

Across 30 payments — averaging $692.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$179
  • AbbVie$155
  • Phathom Pharmaceuticals, Inc.$83
  • Johnson & Johnson$70
  • Lilly USA, LLC$67
  • plus $126 from 4 others

What the payments were for

  • Grants$20,00096%
  • Food & beverage$7834%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,783 in reported general payments places this provider in the 90th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii

Medicare billing

Part B allowed, 2024
$18,359
Medicare patients
89
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl16$380

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →